The ScanVan project aims to address delays in rare cancer diagnostics by utilizing a mobile digital pathology lab. This initiative seeks to enhance access to expertise and streamline the diagnostic process for rare cancers.
Background
Delays in diagnosing rare cancers can significantly impact patient outcomes, as seen in the case of a young patient diagnosed with alveolar soft part sarcoma after a 110-day wait. The centralization of expertise and slow movement of physical specimens contribute to these delays, highlighting the need for innovative solutions in pathology.
Data Highlights
No numerical data or trial results were provided in the source material.
Key Findings
The ScanVan project aims to reduce diagnostic delays for rare cancers by providing mobile digital pathology services.
Access to specialized expertise is often limited, leading to prolonged wait times for patients.
AI technology is proposed as a means to extend the reach of pathologists and improve diagnostic efficiency.
Rare cancers are defined as those occurring less than 40,000 times a year in the U.S., complicating their study and diagnosis.
Data aggregation from multiple institutions is essential for building effective AI algorithms for rare cancer diagnostics.
Clinical Implications
The implementation of mobile digital pathology labs could significantly reduce the time to diagnosis for rare cancers, potentially improving patient outcomes. Access to AI-assisted diagnostic tools may enhance the capabilities of pathologists in community settings.
Conclusion
The ScanVan initiative represents a promising approach to overcoming the challenges of rare cancer diagnostics by leveraging mobile technology and AI to improve access to expertise.
With recent data that RAS inhibition can improve survival in metastatic pancreatic cancer, the optimization of these agents has become a research priority. Minh Than, MD, PhD, a clinical and research ...
On May 28, 2026, the U.S. Food and Drug Administration (FDA) approved the PD-L1 inhibitor durvalumab (Imfinzi) in combination with bacillus Calmette-Guérin (BCG) for the treatment of adult patients wi...
